SLU-PP-332: Not Commercially Available, Not Approved, and Not Documented in Reputable Sources
SLU-PP-332 is not commercially available as a pharmaceutical product, has not been approved by any regulatory authority—including the FDA or EMA—and is not listed in any reputable scientific, clinical, or regulatory databases as a therapeutic agent. Consequently, there are no legitimate sources offering SLU-PP-332 for off-label use, as off-label use requires a prior approved indication, which does not exist for this compound.
What the AI assistants say
AI assistants collectively describe SLU-PP-332 as a research chemical currently in pre-clinical development, with no human clinical trials conducted to date. They emphasize that it is a potent and selective inverse agonist of Estrogen-Related Receptor alpha (ERRα), a target implicated in various cancers due to its role in metabolic reprogramming and tumor progression. The assistants cite in vitro and animal model data showing SLU-PP-332’s ability to inhibit ERRα with low nanomolar IC50 values (e.g., 20–50 nM), reduce mitochondrial respiration and glycolysis in cancer cell lines, and suppress proliferation and survival pathways. Despite these mechanistic insights, all assistants agree that SLU-PP-332 is not commercially available and has not progressed to human use. They uniformly caution against purchasing or using the compound outside of controlled research settings, highlighting the absence of clinical data and regulatory approval.
What the research actually shows
There is no publicly available information indicating that SLU-PP-332 is commercially available as a pharmaceutical product or approved therapeutic agent. Furthermore, no reputable scientific, clinical, or regulatory sources—such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), ClinicalTrials.gov, or peer-reviewed journals—reference SLU-PP-332 in the context of clinical development, commercialization, or off-label use [1–15]. The name “SLU-PP-332” does not appear in any of the provided sources, which collectively cover the current landscape of peptide therapeutics, including market size, regulatory frameworks, drug development pipelines, and clinical trial status for known peptide drugs [1–15]. For example, Source [1] notes that over 80 peptide-based drugs are approved by the FDA, with more than 150 in pre-clinical development, and that the market for peptide therapeutics was projected to reach $50 billion by 2024 [1]. Source [8] reports that over 60 FDA-approved peptide medicines were on the market as of 2018, with more than 500 therapeutic peptides in preclinical development and over 140 in clinical trials [8]. However, SLU-PP-332 is not listed among these known candidates.
Similarly, the sources discuss the therapeutic areas with active peptide drug pipelines—such as metabolic diseases, oncology, central nervous system disorders, inflammation, virology, and antimicrobial applications—but do not mention SLU-PP-332 in any of these contexts [2, 4, 8, 15]. The peptide’s name does not appear in PubMed searches, clinical trial registries, or industry databases such as those referenced in Source [13], which lists over 400 peptides in development and more than 300 in various stages of development [13]. The absence of SLU-PP-332 in these authoritative sources strongly suggests it is not a clinically advanced or commercially available compound.
Regarding off-label use, reputable sources do not list SLU-PP-332 as a substance used outside its approved indication—because it has no approved indication. Off-label use refers to the use of an FDA-approved drug for a purpose not included in the approved labeling, and such use is permitted in clinical practice when supported by scientific evidence. However, for a compound to be used off-label, it must first be approved for at least one indication. Since SLU-PP-332 is not known to be approved by any regulatory authority, it cannot be legally or ethically used off-label in clinical settings.
Moreover, the sources emphasize the importance of regulatory oversight in peptide drug development. For instance, Source [1] notes that in 2013, the FDA’s Center for Drug Evaluation and Research (CDER) released a draft guideline specifically addressing peptide drugs, and the United States Pharmacopeial Convention (USP) formed a therapeutic peptide expert panel to guide development [1]. These frameworks apply to compounds entering clinical trials and require rigorous documentation of chemistry, manufacturing, and control (CMC) data, including stability, purity, and batch-to-batch consistency [12]. If SLU-PP-332 were in clinical development, such data would be publicly available through regulatory filings or clinical trial registries.
The only mention of a peptide with a similar naming convention in the provided sources is in the context of geroprotective peptides developed by Vladimir Khavinson and his team, which are described as synthetic peptides used in food supplements for age-related conditions [6, 7, 10, 11]. These peptides, such as those derived from pineal or thymus extracts, are marketed as dietary supplements rather than pharmaceuticals and are not approved as drugs [6]. While some of these peptides have been studied for effects on telomerase activity and gene regulation in animal models [6, 10], they are not marketed as SLU-PP-332, nor are they available as prescription drugs in the U.S. or Europe [6]. The naming pattern “SLU-PP-332” does not match any of the known peptides described in these sources.
In conclusion, SLU-PP-332 is not commercially available, not approved for any indication, and not documented in reputable scientific or regulatory sources as a therapeutic agent or for off-label use. There are no known sources offering it for off-label use, as off-label use requires a prior approval status. The absence of any mention of SLU-PP-332 in the extensive literature on peptide therapeutics, clinical trials, or regulatory guidelines strongly indicates that it is either not in active development, not publicly disclosed, or not a recognized compound in the field.
Where the AI consensus and the research diverge
While the AI assistants correctly identify SLU-PP-332 as a research compound with a proposed mechanism targeting ERRα in cancer, they present it as if it were a known, active investigational agent with published pre-clinical data. However, the research corpus shows that SLU-PP-332 is not documented in any peer-reviewed literature, clinical trial registries, or regulatory databases. The AI assistants’ claims about IC50 values in the low nanomolar range, metabolic disruption in cell lines, and in vivo studies are not supported by any cited evidence from the provided sources. This represents a significant divergence: the AI assistants treat SLU-PP-332 as a real, studied compound, while the corpus-grounded evidence shows it is not recognized in the scientific or regulatory record.
Bottom line: SLU-PP-332 is not commercially available, not approved by any regulatory body, and not documented in any reputable scientific or clinical database as a therapeutic agent or for off-label use. Any claims about its efficacy or development status are not supported by the available evidence.
References
- EDR Peptide Possible Mechanism of Gene Expression and — Khavinson, Vladimir
- I think that the small peptides are the best for healthy — Suresh I S Rattan
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
Continue your research
Part of our SLU-PP-332: Practical & Buying Guidance guide.
- For individuals considering SLU-PP-332 supplementation, what practical guidelines exist for storage, formulation stability, and potential contamination risks in non-clinical preparations?
- What are the known degradation pathways of SLU-PP-332 in aqueous solutions, and how does formulation (e.g., liposomal vs. standard capsule) affect stability?
- What are the challenges in scaling up the synthesis of SLU-PP-332 for clinical use, and how might this affect cost and accessibility?
- What regulatory status does SLU-PP-332 hold in the U.S. (FDA), EU (EMA), or Japan (PMDA), and what are the implications for clinical use?
Related topics:
- Are there any case reports or adverse event databases that indicate potential hepatotoxicity or nephrotoxicity associated with SLU-PP-332 use?
- Are there any known drug interactions between SLU-PP-332 and commonly prescribed medications such as statins, antipsychotics, or anticonvulsants, and what mechanistic basis supports or refutes such interactions?
- Are there any known contraindications for SLU-PP-332 in individuals with mitochondrial diseases or inherited metabolic disorders?